These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 37567417)
21. Perspectives on the Pure-Tone Audiogram. Musiek FE; Shinn J; Chermak GD; Bamiou DE J Am Acad Audiol; 2017; 28(7):655-671. PubMed ID: 28722648 [TBL] [Abstract][Full Text] [Related]
22. Early hearing threshold changes and peculiarities of audiometric assessments among patients in a drug-resistant tuberculosis treatment center. Sogebi OA; Adefuye BO; Ajayi EA Afr Health Sci; 2021 Mar; 21(1):230-237. PubMed ID: 34394302 [TBL] [Abstract][Full Text] [Related]
23. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study. Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417 [TBL] [Abstract][Full Text] [Related]
24. Prevalence of dead regions in subjects with sensorineural hearing loss. Vinay ; Moore BC Ear Hear; 2007 Apr; 28(2):231-41. PubMed ID: 17496673 [TBL] [Abstract][Full Text] [Related]
25. Extended High-Frequency Smartphone Audiometry: Validity and Reliability. Bornman M; Swanepoel W; De Jager LB; Eikelboom RH J Am Acad Audiol; 2019 Mar; 30(3):217-226. PubMed ID: 30461416 [TBL] [Abstract][Full Text] [Related]
26. Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report. Lu TJ; Amarikwa L; Winn BJ; Inserra M; Dosiou C; Kossler AL Case Rep Ophthalmol; 2023; 14(1):134-139. PubMed ID: 37034380 [TBL] [Abstract][Full Text] [Related]
27. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
28. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy]. Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215 [TBL] [Abstract][Full Text] [Related]
29. A treatise on the thresholds of interoctave frequencies: 1500, 3000, and 6000 Hz. Wilson RH; McArdle R J Am Acad Audiol; 2014 Feb; 25(2):171-86. PubMed ID: 24828218 [TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130 [TBL] [Abstract][Full Text] [Related]
31. Extended High-Frequency Audiometry for Ototoxicity Monitoring: A Longitudinal Evaluation of Drug-Resistant Tuberculosis Treatment. Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W Am J Audiol; 2023 Mar; 32(1):70-80. PubMed ID: 36490390 [TBL] [Abstract][Full Text] [Related]
32. Clinical experience with the words-in-noise test on 3430 veterans: comparisons with pure-tone thresholds and word recognition in quiet. Wilson RH J Am Acad Audiol; 2011; 22(7):405-23. PubMed ID: 21993048 [TBL] [Abstract][Full Text] [Related]
33. Validation Study of Kids Hearing Game: A Self-Administered Pediatric Audiology Application. Kung B; Kunda L; Groff S; Miele E; Loyd M; Carpenter DM Perm J; 2021 May; 25():. PubMed ID: 33970081 [TBL] [Abstract][Full Text] [Related]
34. OtoID: new extended frequency, portable audiometer for ototoxicity monitoring. Dille MF; Jacobs PG; Gordon SY; Helt WJ; McMillan GP J Rehabil Res Dev; 2013; 50(7):997-1006. PubMed ID: 24301436 [TBL] [Abstract][Full Text] [Related]
35. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. Fausti SA; Henry JA; Schaffer HI; Olson DJ; Frey RH; McDonald WJ J Infect Dis; 1992 Jun; 165(6):1026-32. PubMed ID: 1583319 [TBL] [Abstract][Full Text] [Related]
36. High-frequency monitoring for early detection of cisplatin ototoxicity. Fausti SA; Henry JA; Schaffer HI; Olson DJ; Frey RH; Bagby GC Arch Otolaryngol Head Neck Surg; 1993 Jun; 119(6):661-6. PubMed ID: 8499098 [TBL] [Abstract][Full Text] [Related]
37. The incidence of aminoglycoside antibiotic-induced hearing loss. Brummett RE; Morrison RB Arch Otolaryngol Head Neck Surg; 1990 Apr; 116(4):406-10. PubMed ID: 2317321 [TBL] [Abstract][Full Text] [Related]
38. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease. Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314 [TBL] [Abstract][Full Text] [Related]
39. The use of pure-tone audiometry in the assessment of gentamicin auditory toxicity. Davey PG; Jabeen F; Harpur ES; Shenoi PM; Geddes AM Br J Audiol; 1982 May; 16(2):151-4. PubMed ID: 7093565 [TBL] [Abstract][Full Text] [Related]
40. A Large-Scale Examination of Veterans with Normal Pure-Tone Hearing Thresholds within the Department of Veterans Affairs. Billings CJ; Dillard LK; Hoskins ZB; Penman TM; Reavis KM J Am Acad Audiol; 2018; 29(10):928-935. PubMed ID: 30479265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]